ProfoundBio
Seattle, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $112M
Overview
Developing novel antibody-drug conjugates with optimized payloads for oncology.
Oncology
Technology Platform
A proprietary platform for creating next-generation antibody-drug conjugates (ADCs) with novel, potent payloads and optimized linker technology for improved stability and efficacy.
Funding History
1Total raised:$112M
PIPE$112M
Opportunities
Benefiting from renewed and intense strategic interest in ADC platforms from major pharmaceutical companies seeking to bolster their oncology portfolios.
Risk Factors
Clinical failure to show superiority over rapidly advancing standard-of-care ADCs in key solid tumor indications.
Competitive Landscape
Faces significant competition from large pharma and other biotechs in the crowded but high-value ADC market, requiring clear differentiation in linker-payload technology.